Period | Baseline | Hypertonic saline infusion | Post hypertonic saline infusion | ||||
---|---|---|---|---|---|---|---|
0–90 min | 90–150 min | 150–180 min | 180–210 min | 210–240 min | 240–300 min | P (GLM within) | |
U-AQP2 (ng/minute) | |||||||
Placebo | 0.81 (0.66;0.93) | 0.85 (0.71;1.05) | 1.00 (0.81;1.31)* | 1.01 (0.87;1.38)* | 1.07 (0.77;1.26)* | 0.98 (0.80;1.09)* | < 0.001 |
Furosemide | 0.77 (0.66;0.92) | 1.42 (1.18;1.61)* | 1.12 (0.90;1.41)* | 1.14 (0.88;1.46)* | 0.86 (0.72;1.10)* | 0.79 (0.72;0.93) | |
P (GLM between) | 0.553 | ||||||
U-AQP2 /creatinine (ng/mmol) | |||||||
Placebo | 72 (66;84) | 84 (74;87) | 86 (83;104)* | 102 (85;111)* | 90 (77;99)* | 92 (82;98)* | < 0.001 |
Furosemide | 76 (63;83) | 140 (104;150)* | 100 (91;129)* | 121 (84;132)* | 97 (81;107)* | 88 (64;104)* | |
P (GLM between) | 0.186 | ||||||
U-ENaCγ (ng/minute) | |||||||
Placebo | 0.87 (0.71;1.27) | 0.73 (0.60;1.19) | 0.90 (0.76;1.27) | 0.81 (0.70;1.10) | 0.75 (0.64;1.13) | 0.68 (0.60;1.03)* | 0.399 |
Furosemide | 0.92 (0.83;1.26) | 0.87 (0.75;1.03) | 1.06 (0.63;1.31) | 0.83 (0.64;1.12) | 0.81 (0.64;1.04)* | 0.73 (0.63;0.93)* | |
P (GLM between) | 0.806 | ||||||
U-ENaCγ /creatinine (ng/mmol) | |||||||
Placebo | 80 (72;97) | 80 (63;90) | 84 (72;98) | 79 (63;87) | 70 (63;89) | 69 (62;81)* | 0.884 |
Furosemide | 91 (82;99) | 75 (66;131) | 81 (70;116) | 88 (72;16) | 83 (69;107)* | 72 (60;97)* | |
P (GLM between) | 0.487 | ||||||
UAER (μg/min) | |||||||
Placebo | 1 (0;5) | 3 (3;4) | 4 (4;6) | 4 (3;6) | 4 (3;4) | 3 (0;4) | 0.129 |
Furosemide | 1 (0;5) | 0 (0;9) | 0 (0;10) | 4 (1;7) | 4 (2;6) | 3 (2;5) | |
P (GLM between) | 0.167 |